Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IV/IM Susceptible infections 1-2 g daily, increased to 4 g daily in severe infections, given once or in 2 divided doses. Dose >2 g is given via IV inj or infusion. Syphilis 0.5-1 g once daily, increased to 2 g once daily for neurosyphilis for 10-14 days. Lyme disease 2 g once daily for 14-21 days. Prophylaxis of surgical infections 1-2 g as a single dose given 0.5-2 hours before surgery. All doses are given via slow IV inj over 5 minutes, or infused over at least 30 minutes, or deep IM inj. IM Uncomplicated gonorrhoea 250-500 mg as a single dose. Acute otitis media 1-2 g as a single dose.
Hypersensitivity to cephalosporins or history of severe hypersensitivity to other type of β-lactam antibiotic (e.g. penicillins, monobactams, carbapenems). Premature neonates up to a postmenstrual age of 41 weeks (gestational age and chronological age), full term neonates (up to 28 days of age) with hyperbilirubinaemia, jaundice, hypoalbuminaemia, or acidosis requiring IV Ca treatment, or Ca containing infusions.
Special Precautions
Patient with history of allergy to penicillins or any drug, and history of gastrointestinal disease (e.g. colitis), renal lithiasis; hypercalciuria, impaired vit K synthesis or low vit K stores. Severe renal and hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor prothrombin time/INR. Monitor signs and symptoms of hypersensitivity.
Adverse Reactions
Significant: Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)/Lyell's syndrome, hypersensitivity, renal and gallbladder precipitation, pancreatitis secondary to biliary obstruction, renal lithiasis, superinfection. Blood and lymphatic system disorders: Eosinophilia, leucopenia, thrombocytopenia. Gastrointestinal disorders: Diarrhoea, oral candidiasis. General disorders and administration site conditions: Diaphoresis. Injury, poisoning and procedural complications: Pain, induration and tenderness at injection site (IM). Investigations: Increased hepatic enzymes, BUN and serum creatinine; sonographic abnormalities in the gallbladder. Nervous system disorders: Headache, dizziness. Reproductive system and breast disorders: Candidal vaginitis. Skin and subcutaneous tissue disorders: Rash. Vascular disorders: Flushing.
Potentially Fatal: Severe haemolytic anaemia, Clostridium difficile associated diarrhoea (CDAD).
Drug Interactions
May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate.
CIMS Class
ATC Classification
J01DD04 - ceftriaxone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on ceftriaxone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in